Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT02668770	TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies	Fase Fase 1	Date Added 2016-01-29	Ubicación Texas, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Ipilimumab, MGN1703	Etiquetas MSS/ MMRp
NCT ID NCT02617277	TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours	Fase Fase 1	Date Added 2015-11-30	Ubicación Colorado, United States Florida, United States Tennessee, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas AZD1775, MEDI4736	Etiquetas MSS/ MMRp
NCT ID NCT02608385	TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors	Fase Fase 1	Date Added 2015-11-18	Ubicación Illinois, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Pembrolizumab	Etiquetas MSS/ MMRp
NCT ID VAPER	TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer	Fase Fase 1	Date Added 2015-11-17	Ubicación	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Celecoxib, Cyclophosphamide, imiquimod, vaccine	Etiquetas MSS/ MMRp
NCT ID NCT02600949	TitleVacuna peptídica personalizada para el tratamiento de pacientes con cáncer de páncreas o colorrectal avanzado	Fase Fase 1	Date Added 2015-11-09	Ubicación Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02537418	TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	Fase Fase 1	Date Added 2015-09-01	Ubicación Canadá	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas durvalumab, Tremelimumab, Imfinzi	Etiquetas MSS/ MMRp
NCT ID NCT02499328	TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck	Fase Phase 1, Phase 2	Date Added 2015-07-16	Ubicación Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Bélgica Alemania Italia España Reino Unido	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas AZD5069, AZD9150, MEDI4736, tremelimumab (treme)	Etiquetas MSS/ MMRp
NCT ID NCT02484404	TitleEstudio de Fase I/II del Anticuerpo Anti-Ligando de Muerte Programada-1 Durvalumab (MEDI4736) en Combinación con Olaparib y/o Cediranib para Tumores Sólidos Avanzados y Cáncer de Ovario, Mama Triple Negativa, Pulmón, Próstata y Colorrectal Avanzado o Recurrente....	Fase Phase 1, Phase 2	Date Added 2015-06-29	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Cediranib, durvalumab, Olaparib	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02465060	TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Fase Fase 2	Date Added 2015-06-08	Ubicación Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib	Etiquetas MSS/ MMRp
NCT ID NCT02453620	TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	Fase Fase 1	Date Added 2015-05-25	Ubicación California, United States Connecticut, United States Maryland, United States Pennsylvania, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy	Etiquetas MSS/ MMRp

Showing 281 to 290 of 299 entries